文献速递白血病MDS 与骨髓增殖性肿瘤

新型BCL-xL降解剂DT2216在JAK2突变型MPN后AML临床前模型中的疗效

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
PubMed 文献 · Blood · 2025-01-01

研究探讨BCL-xL在MPN后AML中的作用,并测试血小板保留型BCL-xL降解剂DT2216在临床前模型中的疗效。结果显示MPN后AML患者BCL2L1表达高于原发AML,白血病细胞依赖BCL-xL,DT2216单用或联合标准治疗可降解BCL-xL、诱导凋亡并减少肿瘤负荷。

要点

  • MPN后AML患者BCL2L1表达高于原发AML患者。
  • DT2216单用或联合标准AML/MPN治疗可降解BCL-xL并诱导凋亡。
  • DT2216单用或联合阿扎胞苷抑制MPN后AML患者CD34+白血病细胞克隆潜能。

核心结论

  • MPN后AML的生存依赖BCL-xL,DT2216可能为该治疗选择有限的高危白血病亚组提供治疗优势。

研究设计与样本

  • 临床前研究,在MPN后AML模型中使用血小板保留型BCL-xL蛋白水解靶向嵌合体DT2216进行体外和体内测试。

主要发现

  • BCL2L1在MPN后AML患者中的表达水平高于原发AML患者。
  • 单细胞多组学分析显示,同时携带MPN驱动突变和TP53突变的白血病细胞较野生型细胞BCL2L1表达更高,且白血病干细胞、巨核细胞发育和红系祖细胞评分升高。
  • BH3 profiling证实MPN后AML细胞对BCL-xL有强依赖性。
  • DT2216单用或联合标准AML/MPN治疗可有效降解BCL-xL、降低凋亡阈值并诱导MPN后AML细胞凋亡。
  • DT2216通过降解BCL-xL有效清除JAK2突变AML细胞系、诱导多能干细胞来源的造血祖细胞和原代样本中的活细胞,并在细胞系来源异种移植模型中减少体内肿瘤负荷。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) that evolves from myeloproliferative neoplasm (MPN) is known as post-MPN AML. Current treatments do not significantly extend survival beyond 12 months. B-cell lymphoma-extra large (BCL-xL) has been found to be overexpressed in leucocytes from patients with MPN, making it a potential therapeutic target. We investigated the role of BCL-xL in post-MPN AML and tested the efficacy of DT2216, a platelet-sparing BCL-xL proteolysis-targeting chimera, in preclinical models of post-MPN AML. We found that BCL2L1, the gene encoding BCL-xL, is expressed at higher levels in patients with post-MPN AML than in those with de novo AML. Single-cell multiomics analysis revealed that leukemia cells harboring both MPN-driver and TP53 mutations exhibited higher BCL2L1 expression and elevated scores for leukemia stem cell, megakaryocyte development, and erythroid progenitor than wild-type cells. BH3 profiling confirmed a strong dependence on BCL-xL in post-MPN AML cells. DT2216 alone, or in combination with standard AML/MPN therapies, effectively degraded BCL-xL, reduced the apoptotic threshold, and induced apoptosis in post-MPN AML cells. DT2216 effectively eliminated viable cells in JAK2-mutant AML cell lines, induced pluripotent stem cell-derived hematopoietic progenitor cells, primary samples, and reduced tumor burden in cell line-derived xenograft model in vivo by degrading BCL-xL. DT2216, either as a single agent or in combination with azacytidine, effectively inhibited the clonogenic potential of CD34+ leukemia cells from patients with post-MPN AML. In summary, our data indicate that the survival of post-MPN AML is BCL-xL dependent, and DT2216 may offer therapeutic advantage in this high-risk leukemia subset with limited treatment options.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang Z, Skwarska A, Poigaialwar G, et al. Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML. Blood. 2025. PMID: 40163809. doi:10.1182/blood.2024027117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。